Cu-catalyzed enantioselective decarboxylative cyanation <i>via</i> the synergistic merger of photocatalysis and electrochemistry
作者:Yin Yuan、Junfeng Yang、Junliang Zhang
DOI:10.1039/d2sc05428k
日期:——
The development of an efficient and straightforward method for decarboxylative coupling using common alkyl carboxylic acid is of great value. However, decarboxylative coupling with nucleophiles always needs stoichiometric chemical oxidants or substrate prefunctionalization. Herein, we report a protocol for Cu-catalyzed enantioselectivedecarboxylative cyanation via the merger of photocatalysis and
INHIBITORS OF DIACYLGLYCEROL O-ACYLTRANSFERASE TYPE 1 ENZYME
申请人:Abbott Laboratories
公开号:EP2117526A2
公开(公告)日:2009-11-18
[EN] INHIBITORS OF DIACYLGLYCEROL O-ACYLOTRANSFERASE TYPE 1 ENZYME<br/>[FR] INHIBITEURS DE L'ENZYME DIACYLGLYCÉROL O-ACYLOTRANSFÉRASE DE TYPE 1
申请人:ABBOTT LAB
公开号:WO2008067257A2
公开(公告)日:2008-06-05
(EN) Compounds of formula (I), or a pharmaceutically acceptable salt, prodrug, salt of a prodrug, or a combination thereof. Pharmaceutical compositions of formula (I) and related methods for treating or preventing metabolic diseases or conditions.(FR) L'invention concerne des composés représentés par la formule (I), ou un sel pharmaceutiquement acceptable, un promédicament, un sel de promédicament ou une combinaison de ceux-ci. L'invention concerne également des compositions pharmaceutiques de formule (I) et des méthodes associées pour traiter ou prévenir les maladies ou les troubles métaboliques.